Related references
Note: Only part of the references are listed.Hodgkin Lymphoma, Version 2.2020
Richard T. Hoppe et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Alex F. Herrera et al.
BLOOD (2020)
Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study
Sally F. Barrington et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study
Radhakrishnan Ramchandren et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma
Deborah M. Stephens et al.
BLOOD (2019)
Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma
Valeria Spina et al.
BLOOD (2018)
Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial
Andrea Gallamini et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial
Ulrich Duehrsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma
J. M. Connors et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Randomized phase III study comparing an early PET driven treatment deescalation to a not PET-monitored strategy in patients with advanced stages Hodgkin lymphoma: Final analysis of the AHL2011 LYSA study.
Olivier Casasnovas et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial
Marc P. E. Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study
Pier Luigi Zinzani et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816
Oliver W. Press et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi
Francesco Merli et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma
Peter Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Phase II study of interim PET-CT-guided response-adapted therapy in advanced Hodgkin's lymphoma
P. Ganesan et al.
ANNALS OF ONCOLOGY (2015)
Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial
Ranjana H. Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin's Lymphoma
John Radford et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
Sally F. Barrington et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers
Alberto Biggi et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned
Simonetta Viviani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Cost Effectiveness of Positron Emission Tomography in Patients With Hodgkin's Lymphoma in Unconfirmed Complete Remission or Partial Remission After First-Line Therapy
Juliano J. Cerci et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma
Andreas Engert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial
Massimo Federico et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Report on the First International Workshop on interim-PET scan in lymphoma
Michel Meignan et al.
LEUKEMIA & LYMPHOMA (2009)
Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease
Christophe Ferme et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Early interim 2-[18F]Fluoro-2-Deoxy-D-Glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma:: A report from a joint Italian-Danish study
Andrea Gallamini et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Mediastinal bulky tumour in Hodgkin's disease and prognostic value of positron emission tomography in the evaluation of post-treatment residual masses
K Keresztes et al.
ACTA HAEMATOLOGICA (2004)
Share Paper
